Sunday, 15 June 2014

Sanofi Reports Positive Phase 3 Results for Toujeo

Sanofi announce that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia) at any time of day, including night-time events, compared with Lantus® (insulin glargine [rDNA origin] injection, 100 U/mL)

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes

The alliance will initially focus on two key priorities: the development of drug-device combinations and delivery of care management services to improve adherence, simplify insulin treatment, and help people with diabetes better manage their condition (Sanofi)

MANF Is Indispensable for the Proliferation and Survival of Pancreatic ß Cells

We demonstrate that MANF specifically promotes ß cell proliferation and survival, thereby constituting a therapeutic candidate for ß cell protection and regeneration (Cell Reports)

Diabetic cardiomyopathy is associated with defective myocellular copper regulation and both defects are rectified by divalent copper chelation

Myocardial copper deficiency and defective cellular copper transport/trafficking are revealed as key molecular defects underlying LV impairment in diabetes, and TETA-mediated restoration of copper regulation provides a potential new class of therapeutic molecules for DCM (Cardiovascular Diabetology)

No comments:

Post a Comment